Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on December 22, 2008. The filing addresses a corporate governance event under Item 5.02 regarding the departure of a director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a personnel change and contains no financial statements or operational metrics.
Material Changes
The material change reported is the resignation of Evan M. Levine as a member of the Company's Board of Directors, effective immediately on December 22, 2008. The resignation letter stated that Mr. Levine has no disagreement with the Company on any matter relating to its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the immediate resignation event.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Mr. Levine's resignation.
- Confirm whether the resignation was anticipated or if it triggers any specific corporate governance requirements.
- Note that the registrant name in the filing is ADVENTRX Pharmaceuticals, Inc., which may differ from the user's requested company name (Savara Inc.).